Answers are grounded in this paper and cite their sources.
Tamoxifen is effective in reducing breast cancer risk in moderate-risk populations, but it comes with significant risks such as endometrial cancer and thromboembolic events. Clinical decisions should weigh these factors and include regular monitoring.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: